<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521478</url>
  </required_header>
  <id_info>
    <org_study_id>1402-0011</org_study_id>
    <secondary_id>2019-004264-21</secondary_id>
    <nct_id>NCT04521478</nct_id>
  </id_info>
  <brief_title>A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression</brief_title>
  <official_title>A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults with depression (major depressive disorder) for whom standard&#xD;
      treatment with antidepressants alone does not work sufficiently. The purpose of the trial is&#xD;
      to find out whether a medicine called BI 1358894 helps to improve symptoms of depression.&#xD;
      Four different doses of BI 1358894 are tested in the study. Participants continue their&#xD;
      standard antidepressant therapy throughout the study.&#xD;
&#xD;
      Participants are put into 6 groups by chance. Participants in 4 of the 6 groups take&#xD;
      different doses of BI 1358894, and placebo. Participants in the fifth group take quetiapine,&#xD;
      a medicine already used to treat depression, and placebo. Participants in the sixth group&#xD;
      take placebo only.&#xD;
&#xD;
      Participants take BI 1358894, quetiapine, or placebo as tablets twice a day. Placebo tablets&#xD;
      look like BI 1358894 or quetiapine tablets but do not contain any medicine.&#xD;
&#xD;
      Participants are in the study for about 3 months. During this time, they visit the study site&#xD;
      about 8 times and get about 2 phone calls. At the visits, doctors ask participants about&#xD;
      their symptoms.&#xD;
&#xD;
      The results between the BI 1358894 groups, the quetiapine group, and the placebo group are&#xD;
      then compared. The doctors also regularly check the general health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score</measure>
    <time_frame>At week 6</time_frame>
    <description>The MADRS consists of 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thought, suicidal thoughts. MADRS items are rated on a 0-6 continuum (0=no abnormality, 6=severe). The possible total score could range from 0 to 60 (from normal with absence of symptoms to severe depression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response defined as ≥ 50% MADRS reduction from baseline</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in State-Trait Anxiety Inventory (STAI) State and Trait version scores</measure>
    <time_frame>At week 6</time_frame>
    <description>The S-Anxiety scale (STAI Form Y-1) consists of twenty statements that evaluate how respondents feel &quot;right now, at this moment.&quot; The T-Anxiety scale (STAI Form Y-2) consists of twenty statements that assess how people generally feel. Each STAI item is given a weighted score of 1 to 4. A rating of 4 indicates the presence of a high level of anxiety for ten S-Anxiety items and eleven T-Anxiety items (e.g., &quot;I feel frightened,&quot; &quot;I feel upset&quot;). A high rating indicates the absence of anxiety for the remaining ten S-Anxiety items and nine T-Anxiety items (e.g., &quot;I feel calm,&quot; &quot;I feel relaxed&quot;).Scores for both the S-Anxiety and the T-Anxiety scales can vary from a minimum of 20 to a maximum of 80. Higher scores indicate greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression Severity Scale (CGI-S) score</measure>
    <time_frame>At week 6</time_frame>
    <description>The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience with the depression population, a participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) total score</measure>
    <time_frame>At week 6</time_frame>
    <description>The different categories and associated 16 items are: Negative Emotions/Mood: sadness, hopeless/helpless, irritability, anhedonia; Anxiety: feeling overwhelmed, worry; Low Energy: tiredness; Cognition: intrusive thoughts, poor concentration; Sleep Disturbances: general sleep adequacy; Self Harm/Suicide: life not worth living; Low Motivation: lack of drive, no interest in activities; Sense of Self: self-blame; Eating Behavior: poor appetite, overeating. The SMDDS uses a recall of &quot;over the past 7 days&quot; and participants respond to each question using a rating scale between 0 (&quot;Not at all&quot; or &quot;Never&quot;) to 4 (&quot;Extremely&quot; or &quot;Always&quot;). The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">431</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1358894</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894</intervention_name>
    <description>BI 1358894</description>
    <arm_group_label>Treatment group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>quetiapine</description>
    <arm_group_label>Treatment group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        --Established diagnosis of Major Depressive Disorder (MDD), single episode or recurrent, as&#xD;
        confirmed at the time of screening by the Structured Clinical Interview for Diagnostic and&#xD;
        Statistical Manual of Mental Disorders, 5th version (DSM-5) (SCID-5), with a duration of&#xD;
        current depressive episode ≥ 8 weeks and ≤ 18 months at the time of screening visit&#xD;
&#xD;
          -  Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥ 24 at screening, as&#xD;
             confirmed by a trained site based rater AND interactive, computer administered MADRS.&#xD;
             The difference in the rater and computer administered MADRS must not exceed more than&#xD;
             7 points (for details refer to section 6.2). In addition, trial participants must have&#xD;
             a score of ≥ 3 on the Reported Sadness Item on both MADRS scales (computer&#xD;
             administered and rater-administered MADRS)&#xD;
&#xD;
          -  A documented ongoing monotherapy treatment of ≥ 6 weeks at the screening visit, with a&#xD;
             protocol specified Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin&#xD;
             Norepinephrine Reuptake Inhibitor (SNRI) (refer to the ISF) at adequate dose (at least&#xD;
             minimum effective dose as per prescribing information and as confirmed per detectable&#xD;
             drug levels in the screening blood or urine sampling)&#xD;
&#xD;
          -  Male and female participants, 18 to 65 years of age, both inclusively at the time of&#xD;
             consent&#xD;
&#xD;
          -  Women who are of child-bearing potential (WOCBP)1 must be able and willing to use two&#xD;
             methods of contraception which include one highly effective method of birth control&#xD;
             per ICH M3 (R2) that result in a low failure rate of less than 1%, plus one additional&#xD;
             barrier&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial&#xD;
&#xD;
          -  Able to communicate well, and to understand and comply with trial requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Per DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective&#xD;
             disorder, schizophreniform disorder, bipolar disorder, delusional disorder or MDD with&#xD;
             psychotic features as assessed by the Structured Clinical Interview for DSM-5 Clinical&#xD;
             Trials (SCID-5) at the time of screening&#xD;
&#xD;
          -  Diagnosis of any other mental disorder (in addition to those as described in Exclusion&#xD;
             Criterion #1) that was the primary focus of treatment within 6 months prior to&#xD;
             screening or at baseline (as per clinical discretion of the investigator)&#xD;
&#xD;
          -  Diagnosis with antisocial, paranoid, schizoid or schizotypal personality disorder as&#xD;
             per DSM-5 criteria, at the time of screening visit. Any other personality disorder at&#xD;
             screening visit that significantly affects current psychiatric status and likely to&#xD;
             impact trial participation, as per the judgement of investigator&#xD;
&#xD;
          -  Diagnosis of a substance related disorder within 3 months prior to screening visit&#xD;
             (with exception of caffeine and tobacco)&#xD;
&#xD;
          -  History of seizure disorders, stroke, brain tumor or any other major neurological&#xD;
             illness that can impact participation in the trial&#xD;
&#xD;
          -  History of more than 2 unsuccessful monotherapy treatments (at adequate dosage and&#xD;
             duration, per local prescribing information of the product) with an approved&#xD;
             antidepressant medication for the current ongoing major depressive episode. These&#xD;
             include ongoing monotherapy treatment with a protocol specified SSRI or SNRI as&#xD;
             described in Inclusion Criterion #3&#xD;
&#xD;
          -  Any suicidal behavior in the past 12 months prior to screening (per investigator&#xD;
             judgement including an actual attempt, interrupted attempt, aborted attempt, or&#xD;
             preparatory acts or behaviour)&#xD;
&#xD;
          -  Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale&#xD;
             (CSSRS) in the past 3 months prior to screening or at screening or baseline visit&#xD;
             (i.e. active suicidal thought with method and intent but without specific plan, or&#xD;
             active suicidal thought with method, intent and plan)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Macaluso</last_name>
      <phone>+001(205)975-6395</phone>
      <email>mmacaluso@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC (CNS)</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling</last_name>
      <phone>+001(714)799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Shiovitz</last_name>
      <phone>+001(818)990-2671</phone>
      <email>Thomas@shiovitz.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Itzcovich-Schuster</last_name>
      <phone>+001(818)788-0746</phone>
      <email>schuster@smrionline.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Research, Ltd.</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sana Johnson-Quijada</last_name>
      <phone>+001(951)695-6238</phone>
      <email>sana@vikingcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armen Goenjian</last_name>
      <phone>+001(310)523-4200</phone>
      <email>armengoenjian@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Winokur</last_name>
      <phone>+001(860)545-7956</phone>
      <email>awinokur@uchc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Clinical Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaheer Aslam</last_name>
      <phone>+001(239)561-0009</phone>
      <email>Aslam@gulfcoastclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Sarkis</last_name>
      <phone>+001(352)333-0094</phone>
      <email>ok@ehsfamily.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Joyce</last_name>
      <phone>+001(904)281-5757</phone>
      <email>mjoyce@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riesenberg</last_name>
      <phone>+001(404)881-5800</phone>
      <email>rriesenberg@acmr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, LLC</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Zajecka</last_name>
      <phone>+001(847)679-8000</phone>
      <email>john_zajecka@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine-Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Schwasinger-Schmidt</last_name>
      <phone>+001(316)293-3450</phone>
      <email>tschwasinger-schmidt@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hudson</last_name>
      <phone>+001(617)855-2797</phone>
      <email>jhudson@mclean.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kwentus</last_name>
      <phone>+001(601)420-5810</phone>
      <email>jkwentus@precise-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Care and Research Center</name>
      <address>
        <city>O'Fallon</city>
        <state>Missouri</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Ilivicky</last_name>
      <phone>+001(636)244-3589</phone>
      <email>hilivicky@pcrc-stl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elan Cohen</last_name>
      <phone>+001(856)452-9901-x727</phone>
      <email>ecohen@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhdeep Virk</last_name>
      <phone>+001(614)293-3811</phone>
      <email>subhdeep.virk@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Knutson</last_name>
      <phone>+001(425)443-9551</phone>
      <email>drjames.knutson@etresource.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epworth Clinic</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Fitzgerald</last_name>
      <phone>0398054287</phone>
      <email>paul.fitzgerald@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula Therapeutic and Research Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Grunfeld</last_name>
      <phone>0397701579</phone>
      <email>jgrunfeld@ptrg.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Chen</last_name>
      <phone>0390766554</phone>
      <email>leonard.chen@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatry, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Masopust</last_name>
      <phone>+420601344429,420723017788</phone>
      <email>masopjir@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A-shine</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubos Janu</last_name>
      <phone>+420777242101</phone>
      <email>lubos.janu@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AD71 s.r.o.</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Divacka</last_name>
      <phone>+420274772732</phone>
      <email>info@vodopad.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clintrial s.r.o.</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenek Solle</last_name>
      <phone>+420602179709,420222510607</phone>
      <email>zdenek.solle@clintrial.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INEP medical s.r.o.</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Nawka</last_name>
      <phone>+420222201020</phone>
      <email>a.nawka@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Practice for Psychiatry</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Miklos</last_name>
      <phone>+420728615400</phone>
      <email>miklos.tibor@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît Trojak</last_name>
      <phone>+33(0)380293769</phone>
      <email>benoit.trojak@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAB Médical Psyché</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Desbonnet</last_name>
      <phone>+33(0)327881819</phone>
      <email>philippe.desbonnet654@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAB Ambroise Paré</name>
      <address>
        <city>Elancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël Gailledreau</last_name>
      <phone>+33(0)130696300</phone>
      <email>joel.gailledreau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP la Colombière</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Attal</last_name>
      <phone>+33(0)467339702</phone>
      <email>j-attal@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Jacques</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Chirio-Espitalier</last_name>
      <phone>+33(0)240846396</phone>
      <email>marion.chirioespitalier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Giordana</last_name>
      <phone>+33(0)492037777</phone>
      <email>giordana.b@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Carémeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mocrane Abbar</last_name>
      <phone>+33(0)466683426</phone>
      <email>mocrane.abbar@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nematollah Jaafari</last_name>
      <phone>+33(0)549455757</phone>
      <email>nemat.jaafari@ch-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTR Psychiatrique Universitaire</name>
      <address>
        <city>Saint-Cyr-sur-Loire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wissam El-Hage</last_name>
      <phone>+33(0)234378043</phone>
      <email>wissam.elhage@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Englisch</last_name>
      <phone>+49(6131)177335</phone>
      <email>Susanne.Englisch@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Gründer</last_name>
      <phone>+49(621)1703-1900</phone>
      <email>gerhard.gruender@zi-mannheim.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Stralsund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kusserow</last_name>
      <phone>+49(3831)494950</phone>
      <email>kusserow@medizin-hst.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Nord-West</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Springub</last_name>
      <phone>+49(4488)521500</phone>
      <email>joachim.springub@ewetel.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Obudai Egeszsegugyi Centrum</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Kecskes</last_name>
      <phone>+3614367344</phone>
      <email>istvan.kecskes@oec.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janos Rethelyi</last_name>
      <phone>+3612100330</phone>
      <email>rethelyi.janos@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital, Gyongyos</name>
      <address>
        <city>Gyongyos</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Kelemen</last_name>
      <phone>+3637397833</phone>
      <email>junto@t-online.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine Kohnodai Hospital</name>
      <address>
        <city>Chiba, Ichikawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideki Nanasawa</last_name>
      <phone>+81473723501</phone>
      <email>d-nanasawa@hospk.ncgm.go.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroaki Kawasaki</last_name>
      <phone>+81928011011</phone>
      <email>hkawasaki@fukuoka-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaku Mental Clinic</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiromitsu Kaku</last_name>
      <phone>+81925253100</phone>
      <email>kaku.mental.2057@coda.ocn.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuramitsu Hospital</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noriko Tamaru</last_name>
      <phone>+81928111821</phone>
      <email>noritama-1489-dogwood@hyu.bbiq.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arai Clinic</name>
      <address>
        <city>Hyogo, Amagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Arai</last_name>
      <phone>+81664110303</phone>
      <email>psychiatry.a@i.softbank.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kishiro Mental Clinic</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaki Kishiro</last_name>
      <phone>+81449301231</phone>
      <email>kishiro@kishiro-mental.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arata Clinic</name>
      <address>
        <city>Nagasaki, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takatoshi Mori</last_name>
      <phone>+81958487867</phone>
      <email>woods@vega.ocn.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Nara, Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manabu Makinodan</last_name>
      <phone>+81744223051</phone>
      <email>mmm@naramed-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center Neurology and Psychiatry</name>
      <address>
        <city>Tokyo, Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Fujii</last_name>
      <phone>+81423412711</phone>
      <email>tfujii@ncnp.go.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sancha Mental Clinic</name>
      <address>
        <city>Tokyo, Setagaya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenji Shigemori</last_name>
      <phone>+81337957744</phone>
      <email>kenji.shigemori@shore.ocn.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maynds Tower Mental Clinic</name>
      <address>
        <city>Tokyo, Shibuya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobutoshi Kariya</last_name>
      <phone>+81353025288</phone>
      <email>nobutoshi.kariya@train.ocn.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osrodek Badan Klinicznych CLINSANTE S.C.</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Lachut</last_name>
      <phone>+48733473999</phone>
      <email>katarzyna.lachut@clinsante.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specialist Psychiatric Healthcare Centre in Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Galecki</last_name>
      <phone>+48427155985</phone>
      <email>piotr.galecki@umed.lodz.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clin.Research Centre Clinsante SC Ewa Galczak-Nowak,Torun</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Kowalkowski</last_name>
      <phone>+48536865765</phone>
      <email>gkowalkowski@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;Mental Health Research Center&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Morozova</last_name>
      <phone>+74953252082</phone>
      <email>margmorozova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI V. P. Serbsky Nat.Med.Res.Cen.of Psych and Neuro</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Mosolov</last_name>
      <phone>+74959633777</phone>
      <email>profmosolov@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBI of HC &quot;Z. P. Solovyov Scientific and pract psychoneurolog.Cent&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Avedisova</last_name>
      <phone>+74956374000</phone>
      <email>Alla.Avedisova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHI &quot;Reg.Clin.Psychiatric Hosp.of Saint Sophia&quot;</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Ivlieva</last_name>
      <phone>+79063041481</phone>
      <email>iw-irina@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBEI of HE Smolensk State Medical University</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Okhapkin</last_name>
      <phone>+7(4812)450603,74812384468</phone>
      <email>Alexander.Okhapkin@antibiotic.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI Bekhterev Net.Med.Res.Cen.of Psych and Neuro</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Ivanov</last_name>
      <phone>+78126700221</phone>
      <email>profmikhailivanov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;MK-Med&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arina Ledovskikh</last_name>
      <phone>7(812)642?00?33</phone>
      <email>arina.ledovskikh@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;Psychiatric Hospital #1 P.P.Kashchenko&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Raspopov</last_name>
      <phone>+78122518782,78122519333</phone>
      <email>avraspopov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUDr. Beata Dupejová</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Ignjatovicova</last_name>
      <phone>+421911772388</phone>
      <email>dana.ignjatovicova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J and J SMART, s.r.o., psychiatric clinic</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Janikova</last_name>
      <phone>+421252491780</phone>
      <email>dr.evajanikova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MENTUM s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Molcan</last_name>
      <phone>+4212572990111,+421903442910</phone>
      <email>molcan@mentum.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EPAMED s.r.o.</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Palova</last_name>
      <phone>+421902539617</phone>
      <email>palovae@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CENTRUM ZDRAVIA R.B.K, s.r.o., psychiatric clinic</name>
      <address>
        <city>Svidnik</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rastislav Korba</last_name>
      <phone>+421918702477</phone>
      <email>rastislav.korba@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crystal Comfort s.r.o</name>
      <address>
        <city>Vranov nad Toplou</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Vieta</last_name>
      <phone>+34932275400</phone>
      <email>evieta@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Manuel Montes</last_name>
      <phone>+34913368000</phone>
      <email>j_m_montes@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario de Arce</last_name>
      <phone>+34911916523</phone>
      <email>rosario.arce@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de San Juan</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Montejo</last_name>
      <phone>+34923126596</phone>
      <email>amontejo@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Vázquez</last_name>
      <phone>+34942202545</phone>
      <email>javazquez@humv.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

